PRECLINICAL STUDIES
ARI=androgen receptor inhibitor.
Two studies demonstrate low blood-brain barrier penetration with NUBEQA5,6
In a preclinical mouse model
NUBEQA DEMONSTRATED MINIMAL PENETRATION ACROSS THE BLOOD-BRAIN BARRIER
3%
BRAIN-TO-PLASMA RATIO
In a preclinical rat model
NUBEQA DEMONSTRATED LOW BLOOD-BRAIN BARRIER PENETRATION
8%
BLOOD-BRAIN BARRIER PENETRATION
The penetration of NUBEQA across the human blood-brain barrier has not been studied
ARAMIS IS THE LARGEST PHASE III STUDY IN nmCRPC TO DATE2,7,8
- Treatment continued until radiographic disease progression as assessed by conventional imaging (CT, MRI, 99mTc bone scan) by blinded independent central review, discontinuation due to adverse reactions, or withdrawal of consent
*All patients received concurrent ADT (treatment with GnRH analog or previous bilateral orchiectomy).
†Lymph nodes located below the aortic bifurcation as measured by the short axis.
CRPC=castration-resistant prostate cancer; PSADT=prostate-specific antigen doubling time; PSA=prostate-specific antigen; ECOG PS=Eastern Cooperative Oncology Group performance status;
ADT=androgen deprivation therapy; CT=computed tomography; MRI=magnetic resonance imaging; GnRH=gonadotropin-releasing hormone.